SCHEMBL427042

SCHEMBL427042

CC1(N)N=CN=C2N=C(O)N=C21

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL33790 0.71
SCHEMBL30441407 0.60
SCHEMBL3762424 0.58
SCHEMBL30476130 0.55
SCHEMBL9774599 0.55
SCHEMBL17744967 0.52
SCHEMBL3321079 0.51
SCHEMBL7118357 0.51
SCHEMBL9774597 0.50
SCHEMBL22193800 0.50

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220387546-A1 Methods For Treating And/Or Preventing Hypersomnias UNIVERSITE DE LAUSANNE (CH) 2022-12-08 US disclosed
CN-114829386-A Method for treating and/or preventing hypersomnia 洛桑大学 2022-07-29 CN disclosed
WO-2021078631-A1 METHODS FOR TREATING AND/OR PREVENTING HYPERSOMNIAS Université de Lausanne (CH) 2021-04-29 WO disclosed
EP-3812396-A1 METHODS FOR TREATING AND/OR PREVENTING HYPERSOMNIAS Université de Lausanne (CH) 2021-04-28 EP disclosed
WO-2017207623-A1 MIRNA AS BIOMARKERS AND REGULATORS OF CANCER STEM CELLS Université de Lausanne (CH) 2017-12-07 WO disclosed
US-9724404-B2 HPV particles and uses thereof INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2017-08-08 US disclosed
US-20170175112-A1 MIR-21-3P INHIBITORS IN SKIN DISORDERS UNIVERSITE DE LAUSANNE (CH) 2017-06-22 US disclosed
EP-3105330-A1 MiR-21-3p INHIBITORS IN SKIN DISORDERS Université de Lausanne (CH) 2016-12-21 EP disclosed
US-9334311-B2 Chimeric OspA genes, proteins and methods of use thereof BAXALTA INCORPORATED (US) 2016-05-10 US disclosed
US-9139835-B2 Nucleic acid aptamers UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) 2015-09-22 US disclosed
US-20090209045-A1 SCREENING ASSAY GENOPHRENIX LIMITED (GB) 2009-08-20 US disclosed
US-20090023678-A1 Amino Acid Vitamin Ester Compositions for Controlled Delivery of Pharmaceutically Active Compounds IDEXX LABORATORIES, INC. (US) 2009-01-22 US disclosed
US-20060155113-A1 drug screening for identification of agents which modulate the activity of a DNA replication protein as a target for intervention in cancer therapy; carcinoma, adenocarcinoma, lymphoma or leukemia; liver, lung or skin cancer; use of a Ciz1 nucleotide or polypeptide sequence CIZZLE BIOTECHNOLOGY LIMITED (GB) 2006-07-13 US disclosed
US-20060121462-A1 Receptor and screening methods SHEFFIELD, UNIVERSITY OF (GB) 2006-06-08 US disclosed
US-7029892-B1 Serine threonine kinase member, h2520-59 AMGEN, INC. (US) 2006-04-18 US disclosed
US-20060067926-A1 Novel serine threonine kinase member, h2520-59 AMGEN INC. (US) 2006-03-30 US disclosed
US-6881542-B1 Serine threonine kinase member, h2520-59 AMGEN INC. (US) 2005-04-19 US disclosed
EP-0558634-A4 TRIPLEX-FORMING OLIGOMERS CONTAINING MODIFIED BASES GILEAD SCIENCES INC (US) 1995-06-28 EP disclosed
EP-0558634-A1 TRIPLEX-FORMING OLIGOMERS CONTAINING MODIFIED BASES GILEAD SCIENCES, INC. (US) 1993-09-08 EP disclosed
WO-1992009705-A1 TRIPLEX-FORMING OLIGOMERS CONTAINING MODIFIED BASES GILEAD SCIENCES, INC. (US) 1992-06-11 WO disclosed